Successful treatment of a patient with lymphocyte-predominant Hodgkin's lymphoma with yttrium-90-ibritumomab tiuxetan

European Journal of Haematology

Volumn 81, Issue 4, 2008, Pages 322-324

  Zojer, Niklas ^a   Mirzaei, Siroos ^b   Ludwig, Heinz ^a  

^a WILHELMINEN HOSPITAL   (Austria)

^b NONE   (Austria)

Author keywords

Antibodies; Antigens; B cell; CD20; Hodgkin disease; Ibritumomab tiuxetan; Lymphoma; Monoclonal; Radioimmunotherapy; Yttrium radioisotopes

Indexed keywords

ANTIBIOTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DIURETIC AGENT; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; IBRITUMOMAB TIUXETAN; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINCRISTINE;

ADULT; ANAMNESIS; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEVER; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MULTIPLE CYCLE TREATMENT; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; GERMINAL CENTER; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; REMISSION INDUCTION;

EID: 51649088751     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01107.x     Document Type: Article

References (6)

1. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003 101 : 4285 9.
2. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008 111 : 109 11.
3. Horning SJ, Bartlett NL, Breslin S, et al. Results of a prospective phase II trial of limited and extended rituximab treatment in nodular lymphocyte predominant Hodgkin's disease (NLPHD). Blood 2007 110 suppl; abstr 644).
4. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002 20 : 2453 63.
5. Gordon LI, Molina A, Witzig T, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004 103 : 4429 31.
6. Wiseman GA, Witzig TE. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2005 20 : 185 8.